- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Intermittent Meropenem therapy as effective as continuous therapy in sepsis patients: JAMA
Continuous meropenem medication did not enhance the composite outcome of death and the development of pandrug-resistant or substantially drug-resistant bacteria at day 28 in critically sick sepsis patients as compared to intermittent delivery, says an article published in the Journal of American Medical Association.
An extremely popular beta-lactam antibiotic is meropenem. When administered as a continuous infusion to maintain drug levels above the minimum inhibitory concentration, meropenem demonstrates its highest pharmacodynamic effectiveness. Continuous meropenem dosing may lead to better clinical results than intermittent administration. Giacomo Monti and his team conducted this study to see if continuous meropenem administration in critically ill sepsis patients reduces a composite of mortality and the emergence of pandrug-resistant or extensively drug-resistant bacteria in comparison to intermittent administration.
This was a randomized, double-blind clinical trial that enrolled patients in 31 intensive care units at 26 hospitals in 4 nations (Croatia, Kazakhstan, Italy, and Russia) who were critically sick and had sepsis or septic shock and had been administered meropenem by their treating doctors. Between June 5, 2018, and August 9, 2022, patients were enrolled; the last 90-day follow-up was finished in November 2022. Meropenem, an antibiotic, was randomly administered to patients in equal doses either continuously (n = 303) or intermittently (n = 304). On day 28, a composite of all-cause mortality and the appearance of microorganisms that were extensively or widely drug-resistant was the main result.
The key findings of this study were:
All 607 patients underwent the 90-day mortality follow-up and were counted in the measurement of the 28-day main outcome.
Septic shock was present in 369 individuals, or 61% of the total.
The median length of meropenem treatment was 11 days (IQR, 6-17 days), while the median time from hospital admission to randomization was 9 days.
There was just one crossover occurrence noted.
In the continuous administration group, 142 patients (47%) and in the intermittent administration group, 149 patients (49%) experienced the main result.
None of the four secondary results reached statistical significance.
There were no documented seizures or allergic reactions associated with the trial medication.
Both the continuous treatment group and the intermittent administration group had death rates of 42% at 90 days.
Reference:
Monti, G., Bradić, N., Marzaroli, M., Konkayev, A., Fominskiy, E., Kotani, Y., Likhvantsev, V. V., Momesso, E., Nogtev, P., Lobreglio, R., Redkin, I., Toffoletto, F., Scandroglio, A. M., Gallicchio, F., … Ballestra, M. (2023). Continuous vs Intermittent Meropenem Administration in Critically Ill Patients With Sepsis. In JAMA. American Medical Association (AMA). https://doi.org/10.1001/jama.2023.10598
Neuroscience Masters graduate
Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751